Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know.

Biotech company Biogen (NASDAQ:BIIB) reported in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its non-GAAP ...

If you are wondering whether Biogen's current share price reflects its true worth, you are not alone. This article is built to help you frame that question clearly. Biogen recently closed at US$183.38 ...

Biogen BIIB reported first-quarter 2026 adjusted earnings per share (EPS) of $3.57, which significantly beat the Zacks ...

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in both sales and profit.

Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...

The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...

Biogen Inc (NASDAQ:BIIB) reflects mixed sentiment as Nasdaq composite trends highlight biotech sector dynamics.

Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...